AASLD Voice of China | Dr. Zhenhuan Cao’s Team: The Impact of Hepatic Steatosis on Antiviral Therapy in Patients with Chronic Hepatitis B
From November 10th to 14th, 2023, the annual highlight in the field of hepatology—the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023 was grandly held in Boston, USA. Dr. Zhenhuan Cao from Beijing You'an Hospital, Capital Medical University, as the corresponding author, presented a research abstract at the conference, revealing the influence of hepatic steatosis on the efficacy of antiviral therapy in patients with chronic hepatitis B (CHB). The results suggest that hepatic steatosis has no significant impact on the effectiveness of nucleos(t)ide analogs (NAs) and pegylated interferon (PEG-IFN) treatment [1]. Hepatology Digest reports on this, and the relevant content is shared below.